The FDA on Wednesday cleared the sale of the first blood test to evaluate concussion in adults. The agency said a blood test could help avoid unnecessary computed tomography scans of the head, because most patients evaluated for concussion do not have detectable intracranial lesions.
The FDA on Wednesday cleared the sale of the first blood test to evaluate concussion in adults. The agency said a blood test could help avoid unnecessary computed tomography (CT) scans of the head, because most patients evaluated for concussion do not have detectable intracranial lesions.
The approval was granted to Banyan Biomarkers, Inc. The test, called the Brain Trauma Indicator, was approved in fewer than 6 months as part of the FDA’s breakthrough devices program.
The test works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury. Levels of these blood proteins after concussion can help predict which patients may have intracranial lesions visible by CT scan and which will not. Being able to predict whether patients have a low probability of intracranial lesions can help healthcare professionals manage patients and decide whether or not to perform a CT scan. Test results can be available within 3 to 4 hours.
Avoiding scans when possible will cut unnecessary radiation exposure as well as the cost of the scans, the FDA said in a statement.
“Today’s action supports the FDA’s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging—an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,” said FDA Commissioner Scott Gottlieb, MD.
According to the CDC, in 2013, there were approximately 2.8 million emergency department visits, hospitalizations, and deaths related to concussions. Of these cases, concussion-related head injuries contributed to the deaths of nearly 50,000 patients.
In a multicenter clinical study, the blood test was able to predict the presence of intracranial lesions on a CT scan 97.5% of the time and identified those who did not have intracranial lesions on a CT scan 99.6% of the time. These findings indicate that the test can reliably predict the absence of intracranial lesions.
According to the Choosing Wisely campaign from the ABIM Foundation, brain scans are usually not useful for diagnosing concussions. Choosing Wisely aims to encourage conversations between clinicians and patients by educating patients about care that is supported by evidence, not duplicative, free from harm, and necessary.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More